Biocon Biologics Ltd, a global biosimilars company, has partnered with the National Cancer Society of Malaysia (NCSM) to launch a Patient Assistance Programme (PAP) aimed at improving access to affordable, high-quality biosimilars for underserved cancer patients in Malaysia. The partnership combines Biocon’s expertise in biosimilars with NCSM’s community outreach to enhance cancer care accessibility and affordability in Malaysia. The program will initially provide Trastuzumab, a biosimilar, to cancer patients facing treatment delays due to budget constraints.
Under the partnership, Biocon Biologics will provide quality-assured biosimilars from its oncology portfolio, including Trastuzumab, Pegfilgrastim, and Bevacizumab, to NCSM, which will manage patient enrolment and medicine supply as part of its healthcare services. The collaboration marks a meaningful step forward in expanding access to high-quality oncology biosimilars for cancer patients in need. Biocon Biologics aims to ease the treatment burden for underserved populations and strengthen Malaysia’s efforts to deliver inclusive, patient-centric healthcare.
The partnership is a significant step forward for Biocon Biologics, which has previously expanded access to diabetes care in Malaysia, serving over 345,000 patients. The company is now focusing on oncology through strategic partnerships like this one. The Memorandum of Understanding (MoU) was signed during the National Cancer Congress Malaysia 2025 event, emphasizing a commitment to improving patient-centric healthcare. Ratish Trehan, Head of Commercial, Emerging Markets, Biocon Biologics, and Dr Saunthari Somasundaram, NCSM President, signed the MoU in the presence of Health Minister Dzulkefly Ahmad.
NCSM is Malaysia’s first not-for-profit cancer organization, providing education, care, and support services. The organization has earned a strong reputation for fair practices and community trust, making it an ideal partner for Biocon Biologics’ PAP initiative in Malaysia. The partnership is expected to positively impact thousands of lives and contribute to Malaysia’s efforts to deliver inclusive, patient-centric healthcare. With this collaboration, Biocon Biologics and NCSM aim to make a meaningful difference in the lives of cancer patients in Malaysia, providing them with access to affordable, high-quality biosimilars and improving their overall quality of life.